Skip to main content

Advertisement

SpringerLink
Log in

Vascular Endothelial Growth Factor (VEGF) Inhibitor Cardiotoxicity: What Should We Know?

  • Cardio-oncology (M Fradley, Section Editor)
  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Abstract

Purpose of review

Cancer therapy-induced cardiovascular toxicity is a growing clinical problem with many unanswered questions about the optimal screening, prevention, and management, especially in patients treated with new targeted drugs. Among them, the use of vascular endothelial growth factor inhibitors (VEGFi) has become one of the most promising strategies to successfully approach a wide range of tumors. However, they have been associated with important cardiovascular complications such as systemic hypertension, heart failure, QTc prolongation, and venous and arterial thrombosis. This review addresses a multidisciplinary management of VEGFi-induced cardiotoxicity.

Recent findings

Optimal management of antiangiogenic drugs side effects is challenging due to limited evidence-based recommendations. The detection and aggressive treatment of hypertension and other cardiovascular risk factors is essential to minimize treatment interruptions, heart failure, and cardiac arrhythmias. Additionally a close monitoring of signs and symptoms that may raise the suspicion of venous or arterial thromboembolic events is recommended. For that purpose, cardio-oncology approach aims to facilitate cancer therapy and to promote cardio-oncology research.

Summary

VEFGi use is generally limited by uncontrolled hypertension that may trigger heart failure and cardiac arrhythmias. Therefore, a comprehensive cardio-oncology approach is needed to establish effective preventive and monitoring protocols.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. •• Zamorano JL, Lancellotti P, Muñoz DR, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2768–801. https://doi.org/10.5603/KP.2016.0156 ESC consensus document highlighting main CV side effects of VEGFi and basic CV toxicity management.

    Article  PubMed  Google Scholar 

  2. Lopez-Fernandez T, Martin Garcia A, Santaballa Beltran A, Monterro Luis A, García Sanza R, Mazón Ramos P, et al. Cardio-onco-hematology in clinical practice. Position paper and recommendations. Rev Esp Cardiol (Engl Ed). 2017;70(6):474–86. https://doi.org/10.1016/j.rec.2016.12.041.

    Article  Google Scholar 

  3. •• Lancellotti P, Suter TM, Lopez-Fernandez T, Galderisi M, Lyon AR, Van der Meer P, et al. Cardio-oncology services: rationale, organization, and implementation: a report from the ESC Cardio-Oncology council. Eur Heart J. 2019;40(22):1756–63. https://doi.org/10.1093/eurheartj/ehy453 This article summarizes tips and tricks to organize a cardio oncology service with practical recommendation regarding human and technical resources needed as well as standards for CO team practices.

    Article  PubMed  Google Scholar 

  4. de Boer RA, Meijers WC, van der Meer P, van Veldhuisen DJ. Cancer and heart disease: associations and relations. Eur J Heart Fail. 2019;21:1515–25. https://doi.org/10.1002/ejhf.1539.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, et al. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation. 2018;137:e30–66. https://doi.org/10.1161/CIR.0000000000000556.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Campia U, Moslehi JJ, Amiri-Kordestani L, Barac A, Beckman JA, Chism DD, et al. Cardio-oncology: vascular and metabolic perspectives: a scientific statement from the American Heart Association. Circulation. 2019;139:e579–602. https://doi.org/10.1161/CIR.0000000000000641.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Li W, Croce K, Steensma DP, McDermott DF, Ben-Yehuda O, Moslehi J. Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors. J Am Coll Cardiol. 2015;66:1160–78. https://doi.org/10.1016/j.jacc.2015.07.025.

    Article  PubMed  Google Scholar 

  8. Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016;375(15):1457–67. https://doi.org/10.1056/NEJMra1100265.

    Article  CAS  PubMed  Google Scholar 

  9. Hall PS, Harshman LC, Srinivas S, Witteles RM. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC Heart Fail. 2013;1(1):72–8. https://doi.org/10.1016/j.jchf.2012.09.001.

    Article  PubMed  Google Scholar 

  10. Ewer MS, Suter TM, Lenihan DJ, Niculescu L, Breazna A, Demetri GD, et al. Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events. Eur J Cancer. 2014;50(12):2162–70. https://doi.org/10.1016/j.ejca.2014.05.013.

    Article  CAS  PubMed  Google Scholar 

  11. Touyz RM, Herrmann J. Cardiotoxicity with vascular endothelial growth factor inhibitor therapy. NPJ Precis Oncol. 2018;2:13. https://doi.org/10.1038/s41698-018-0056-z.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Waliany S, Sainani KL, Park LS, Zhang CA, Srinivas S, Witteles RM. Increase in blood pressure associated with tyrosine kinase inhibitors targeting vascular endothelial growth factor. J Am Coll Cardiol Cardio Onc. 2019;1:24–36. https://doi.org/10.1016/j.jaccao.2019.08.012.

    Article  Google Scholar 

  13. Herrmann J, Yang EH, Iliescu CA, Cilingiroglu M, Charitakis K, Hakeem A, et al. Vascular toxicities of cancer therapies: the old and the new-an evolving avenue. Circulation. 2016;133:1272–89. https://doi.org/10.1161/CIRCULATIONAHA.115.018347.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH. Cardiovascular complications of cancer therapy best practices in diagnosis, prevention, and management: Part 2. J Am Coll Cardiol. 2017;70:2552–65. https://doi.org/10.1016/j.jacc.2017.09.1095.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Alameddine RS, Yakan AS, Skouri H, Mukherji D, Temraz S, Shamseddine A. Cardiac and vascular toxicities of angiogenesis inhibitors: the other side of the coin. Rev Crit Rev Oncol Hematol. 2015;96(2):195–205. https://doi.org/10.1016/j.critrevonc.2015.05.004.

    Article  PubMed  Google Scholar 

  16. Abdel-Qadir H, Ethier J-L, Lee DS, Thavendiranathan P, Amir E. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-Analysis. Cancer Treat Rev. 2017;53:120–7. https://doi.org/10.1016/j.ctrv.2016.12.002.

    Article  CAS  PubMed  Google Scholar 

  17. Patel S, Dushenkov A, Jungsuwadee P, Krishnaswami A, Barac A. Team-based approach to management of hypertension associated with angiogenesis inhibitors. J Cardiovasc Transl Res. https://doi.org/10.1007/s12265-020-10024-5.

  18. RxList. Available at: https://www.rxlist.com/script/main/hp.asp. Accessed 15 Jun 2020

  19. Electronic Medicines Compendium. Available at: https://www.medicines.org.uk/emc. Accessed 15 Jun 2020

  20. •• Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31:171–90. https://doi.org/10.1016/j.annonc.2019.10.023 Updated 2020 ESMO cardio-oncology guidelines.

    Article  CAS  PubMed  Google Scholar 

  21. •• Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020. https://doi.org/10.1002/ejhf.1920 Online ahead of print, HFA position statement focused on practical baseline cardiotoxicity risk stratification.

  22. Piepoli MF, Abreu A, Albus C, Ambrosetti M, Brotons C, Catapano AL, et al. Update on cardiovascular prevention in clinical practice: a position paper of the European Association of Preventive Cardiology of the European Society of Cardiology. Eur J Prev Cardiol. 2020;27(2):181–205. https://doi.org/10.1177/2047487319893035.

    Article  PubMed  Google Scholar 

  23. Bravo-Jaimes K, Marcellon R, Varanitskaya L, Kim PY, Iliescu C, Gilchrist SC, et al. Opportunities for improved cardiovascular disease prevention in oncology patients. Curr Opin Cardiol. 2020. https://doi.org/10.1097/HCO.0000000000000767 Online ahead of print.

  24. Hershman DL, Accordino MK, Shen S, Buono D, Crew KD, Kalinsky K, et al. Association between nonadherence to cardiovascular risk factor medications after breast cancer diagnosis and incidence of cardiac events. Cancer. 2020;126:1541–9. https://doi.org/10.1002/cncr.32690.

    Article  CAS  PubMed  Google Scholar 

  25. Dixon DL, Patterson JA, Gatewood S, Kaefer T, Jadallah J, Curtis M, et al. Development and feasibility of a community pharmacy-driven 24-hour ambulatory blood pressure monitoring service. J Am Pharm Assoc (2003). 2020:S1544–3191(20)30273–9. https://doi.org/10.1016/j.japh.2020.06.007.

  26. Čelutkienė J, Pudil R, López-Fernández T, Grapsa J, Nihoyannopoulos P, Bergler-Klein J, et al. The role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail. 2020. https://doi.org/10.1002/ejhf.1957 Online ahead of print.

  27. Plana JC, Thavendiranathan P, Bucciarelli-Ducci C, Lancellotti P. Multi-modality imaging in the assessment of cardiovascular toxicity in the cancer patient. JACC Cardiovasc Imaging. 2018;11(8):1173–86. https://doi.org/10.1016/j.jcmg.2018.06.003.

    Article  PubMed  Google Scholar 

  28. Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc. 2014;89(9):1287–306. https://doi.org/10.1016/j.mayocp.2014.05.013.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26(32):5204–12. https://doi.org/10.1200/JCO.2007.15.6331.

    Article  PubMed  Google Scholar 

  30. Nhola LF, Abdelmoneim SS, Villarraga HR, Kohli M, Grothey A, Bordun KA, et al. Echocardiographic assessment for the detection of cardiotoxicity due to vascular endothelial growth factor inhibitor therapy in metastatic renal cell and colorectal cancers. J Am Soc Echocardiogr. 2019;32(2):267–76. https://doi.org/10.1016/j.echo.2018.09.019.

    Article  PubMed  Google Scholar 

  31. Cohen JB, Geara AS, Hogan JJ, Raymond R. Townsend. Hypertension in cancer patients and survivors. Epidemiology, diagnosis, and management. J Am Coll Cardiol Cardio Onc. 2019;1:238–51. https://doi.org/10.1016/j.jaccao.2019.11.009.

    Article  Google Scholar 

  32. Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, et al. Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA Cancer J Clin. 2016;66:309–25. https://doi.org/10.3322/caac.21341.

    Article  PubMed  Google Scholar 

  33. Brinda B, Viganego F, Vo T, Dolan D, Fradley MG. Anti-VEGF-induced hypertension: a review of pathophysiology and treatment options. Curr Treat Options Cardio Med. 2016;18:33. https://doi.org/10.1007/s11936-016-0452-z.

    Article  Google Scholar 

  34. Fraeman KH, Nordstrom BL, Luo W, Landis SH, Shantakumar S. Incidence of new-onset hypertension in cancer patients: a retrospective cohort study. Int J Hypertens. 2013;2013:379252. https://doi.org/10.1155/2013/379252.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Al-Kindi SG, Oliveira GH. Prevalence of preexisting cardiovascular disease in patients with different types of cancer: the unmet need for onco-cardiology. Mayo Clin Proc. 2016;91(1):81–3. https://doi.org/10.1016/j.mayocp.2015.09.009.

    Article  PubMed  Google Scholar 

  36. Scartozzi M, Galizia E, Chiorrini S, Giampieru R, Berardi C, Pierantoni C, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol. 2009;20:227–30. https://doi.org/10.1093/annonc/mdn637.

    Article  CAS  PubMed  Google Scholar 

  37. Maurea N, Spallarossa P, Cadeddu C, Madonna R, Mele D, Monte I, et al. A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. J Cardiovasc Med (Hagerstown). 2016;17(Suppl 1) Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection:e93–e104. https://doi.org/10.2459/JCM.0000000000000383.

  38. Abdel-Qadir H, Ethier JL, Lee DS, Thavendiranathan P, Amir E. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and metaanalysis. Cancer Treat Rev. 2017;53:120–7. https://doi.org/10.1016/j.ctrv.2016.12.002.

    Article  CAS  PubMed  Google Scholar 

  39. Totzeck M, Mincu RI, Mrotzek S, Schadendorf D, Rassaf T. Cardiovascular diseases in patients receiving small molecules with antivascular endothelial growth factor activity: a meta-analysis of approximately 29,000 cancer patients. Eur J Prev Cardiol. 2018;25:482–94. https://doi.org/10.1177/2047487318755193.

    Article  PubMed  Google Scholar 

  40. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). J Hypertens. 2018;36(10):1953–2041. https://doi.org/10.1097/HJH.0000000000001940.

    Article  CAS  PubMed  Google Scholar 

  41. Bottinor WJ, Shuey MM, Manouchehri A, Farber-Eger EH, Xu M, Nair D, et al. Renin-angiotensin-aldosterone system modulates blood pressure response during vascular endothelial growth factor receptor inhibition. J Am Coll Cardiol Cardio Onc. 2019;1:14–23. https://doi.org/10.1016/j.jaccao.2019.07.002.

    Article  Google Scholar 

  42. Ghatalia P, Morgan CJ, Je Y, Nguyen PL, Trinh QD, Choueiri TK, et al. Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Crit Rev Oncol Hematol. 2015;94:228–37. https://doi.org/10.1016/j.critrevonc.2014.12.008.

    Article  PubMed  Google Scholar 

  43. Choueiri TK, Mayer EL, Je Y, Rosenberg JE, Nguyen PL, Azzi GR, et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol. 2011;29(6):632–8. https://doi.org/10.1200/JCO.2010.31.9129.

    Article  CAS  PubMed  Google Scholar 

  44. Chu Tammy F, Rupnick Maria A, Kerkela R, Dallabrida Susan M, Zurakowski D, Nguyen L, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370(9604):2011–9. https://doi.org/10.1016/S0140-6736(07)61865-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JF, Coats AS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail. 2016;18(8):891–975. https://doi.org/10.1002/ejhf.592.

    Article  PubMed  Google Scholar 

  46. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137–61. https://doi.org/10.1161/CIR.0000000000000509.

    Article  PubMed  Google Scholar 

  47. Hassan SA, Palaskas N, Kim P, Iliescu C, Lopez-Mattei J, Mouhayar E, et al. Chemotherapeutic agents and the risk of ischemia and arterial thrombosis. Curr Atheroscler Rep. 2018;20:10. https://doi.org/10.1007/s11883-018-0702-5.

    Article  CAS  PubMed  Google Scholar 

  48. Muñoz Martín AJ, Font Puig C, Navarro Martín LM, Borrega García P, Martín Jiménez M. Clinical guide SEOM on venous thromboembolism in cancer patients. Clin Transl Oncol. 2014;16:1079–90. https://doi.org/10.1007/s12094-014-1238-y.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Faruque LI, Lin M, Battistella M, Wiebe N, Reiman T, Hemmelgarn B, et al. Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer. PLoS One. 2014;9:e101145. https://doi.org/10.1371/journal.pone.0101145.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008;300:2277–85. https://doi.org/10.1001/jama.2008.656.

    Article  CAS  PubMed  Google Scholar 

  51. Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol. 2010;28:2280–5. https://doi.org/10.1200/JCO.2009.27.2757.

    Article  CAS  PubMed  Google Scholar 

  52. Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol. 2010;49:287–97. https://doi.org/10.3109/02841860903524396.

    Article  CAS  PubMed  Google Scholar 

  53. Hang XF, Xu WS, Wang JX, Wang L, Xin HG, Zhang RQ, et al. Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol. 2011;67:613–23. https://doi.org/10.1007/s00228-010-0988-x.

    Article  CAS  PubMed  Google Scholar 

  54. Je Y, Schutz FA, Choueiri TK. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol. 2009;10:967–74. https://doi.org/10.1016/S1470-2045(09)70222-0.

    Article  CAS  PubMed  Google Scholar 

  55. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38(5):496–520. https://doi.org/10.1200/JCO.19.01461.

    Article  PubMed  Google Scholar 

  56. Buza V, Rajagopalan B, Curtis AB. Cancer treatment–induced arrhythmias focus on chemotherapy and targeted therapies. Circ Arrhythm Electrophysiol. 2017;10:e005443. https://doi.org/10.1161/CIRCEP.117.005443.

    Article  PubMed  Google Scholar 

  57. López-Fernández T, Martín-García A, Roldán Rabadán I, Mitroi C, Mazón Ramos P, Díez-Villanueva P, et al. Atrial fibrillation in active cancer patients: expert position paper and recommendations. Rev Esp Cardiol. 2019;72(9):749–59. https://doi.org/10.1016/j.rec.2019.03.019.

    Article  PubMed  Google Scholar 

  58. Wirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18:1609–78. https://doi.org/10.1093/europace/euw295.

    Article  Google Scholar 

  59. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39:1330–93. https://doi.org/10.1093/eurheartj/ehy136.

    Article  CAS  PubMed  Google Scholar 

  60. Escobar C, Martí-Almor J, Pérez Cabeza A, Martínez-Zapata MJ. Direct oral anticoagulants versus vitamin K antagonists in real-life patients with atrial fibrillation. A systematic review and meta-analysis. Rev Esp Cardiol (Engl Ed), 2019. 72(4):305–16. https://doi.org/10.1016/j.rec.2018.03.009.

  61. Porta-Sánchez A, Gilbert C, Spears D, Amir E, Chan J, Nanthakumar K, et al. Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: a systematic review. Am Heart Assoc. 2017;6:e007724. https://doi.org/10.1161/JAHA.117.007724.

    Article  Google Scholar 

  62. Roden DM. A current understanding of drug-induced QT prolongation and its implications for anticancer therapy. Cardiovasc Res. 2019;115:895–903. https://doi.org/10.1093/cvr/cvz013.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardio-Oncology Unit, Cardiology Department, La Paz University Hospital, IdiPAZ, CIBER CV, Madrid, Spain

    Teresa López-Fernández MD, FICOS (Fellow of the International Cardio-Oncology Society)

  2. Servicio de Cardiología, Hospital Universitario La Paz, Hospital General Planta 1, Paseo de la Castellana 261, 28043, Madrid, Spain

    Teresa López-Fernández MD, FICOS (Fellow of the International Cardio-Oncology Society)

  3. Cardio-Oncology Department, Roffo Institute, Buenos Aires, Argentina

    Andrés Daniele MD

  4. Heart Transplant Sanatorio Sagrado Corazon, Buenos Aires, Argentina

    Vanessa Gregorietti MD

Authors
  1. Teresa López-Fernández MD, FICOS (Fellow of the International Cardio-Oncology Society)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrés Daniele MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vanessa Gregorietti MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

TLF contributed to conception and design, contributed to analysis and interpretation, and drafted the manuscript. AD contributed to conception and design and drafted the manuscript. VG contributed to conception and design and drafted the manuscript. Images and tables are originals.

Corresponding author

Correspondence to Teresa López-Fernández MD, FICOS (Fellow of the International Cardio-Oncology Society).

Ethics declarations

Conflict of Interest

Teresa López-Fernández, Andrés Daniele and Vanesa Gregorietti declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Cardio-oncology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

López-Fernández, T., Daniele, A. & Gregorietti, V. Vascular Endothelial Growth Factor (VEGF) Inhibitor Cardiotoxicity: What Should We Know?. Curr Treat Options Cardio Med 22, 74 (2020). https://doi.org/10.1007/s11936-020-00866-2

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11936-020-00866-2

Keywords

Search

Navigation